Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

108.07 +0.25 (+0.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 958,802
Open 106.01
Bid (Size) 108.09 (3)
Ask (Size) 118.10 (1)
Prev. Close 107.82
Today's Range 106.01 - 109.30
52wk Range 95.49 - 148.06
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching
Jazz Pharmaceuticals (NASDAQ:JAZZ) appears undervalued with strong profitability and reasonable growth, making it a potential pick for value investors. 
Via Chartmill
JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s... 
Via StockStory
Topics World Trade
Exposures Tariff

Performance

YTD
-12.7%
-12.7%
1 Month
+3.7%
+3.7%
3 Month
-20.5%
-20.5%
6 Month
-14.7%
-14.7%
1 Year
+4.0%
+4.0%

More News

Read More
Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Jazz Pharmaceuticals (NASDAQ:JAZZ) Misses Q1 Sales Targets
Via StockStory
Earnings Scheduled For May 6, 2025
Via Benzinga
Preview: Jazz Pharmaceuticals's Earnings
Via Benzinga
Earnings To Watch: Jazz Pharmaceuticals (JAZZ) Reports Q1 Results Tomorrow
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Via StockStory
Despite its impressive fundamentals,JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) remains undervalued.
Via Chartmill
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ): A Potential Undervalued Stock
Via Chartmill
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead
Via StockStory
A Glimpse Into The Expert Outlook On Jazz Pharmaceuticals Through 12 Analysts
Via Benzinga
3 Small-Cap Stocks in the Doghouse
Via StockStory
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
3 Value Stocks Skating on Thin Ice
Via StockStory
Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is a compelling option with its solid fundamentals.
Via Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
From Brodsky & Smith LLC
Via GlobeNewswire
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
Via Benzinga
Topics Earnings
Exposures Financial
3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX
Via Talk Markets
Topics Stocks / Equities
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
Via Benzinga
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
From Chimerix, Inc.; Jazz Pharmaceuticals plc
Via GlobeNewswire
Novartis Earns Near-Best Overall Rating As Profit Growth Climbs
Via Investor's Business Daily

Frequently Asked Questions

Is Jazz Pharmaceuticals plc - Ordinary Shares publicly traded?
Yes, Jazz Pharmaceuticals plc - Ordinary Shares is publicly traded.
What exchange does Jazz Pharmaceuticals plc - Ordinary Shares trade on?
Jazz Pharmaceuticals plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Jazz Pharmaceuticals plc - Ordinary Shares?
The ticker symbol for Jazz Pharmaceuticals plc - Ordinary Shares is JAZZ on the Nasdaq Stock Market
What is the current price of Jazz Pharmaceuticals plc - Ordinary Shares?
The current price of Jazz Pharmaceuticals plc - Ordinary Shares is 108.07
When was Jazz Pharmaceuticals plc - Ordinary Shares last traded?
The last trade of Jazz Pharmaceuticals plc - Ordinary Shares was at 05/23/25 04:00 PM ET
What is the market capitalization of Jazz Pharmaceuticals plc - Ordinary Shares?
The market capitalization of Jazz Pharmaceuticals plc - Ordinary Shares is 6.73B
How many shares of Jazz Pharmaceuticals plc - Ordinary Shares are outstanding?
Jazz Pharmaceuticals plc - Ordinary Shares has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.